Serina Therapeutics, Inc. SEC filings SER
Serina Therapeutics, Inc. has 519 filings in SEC EDGAR's recent list, going back to Jul 10, 2017. Its latest annual report, Form 10-K, was filed on Mar 25, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 9, 2026 (bylaw or fiscal year change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 31, 2026 | — |
| EFFECT | Filing | Jun 3, 2026 | — |
| CORRESP | Letter to the SEC | Jun 1, 2026 | — |
| UPLOAD | Letter from the SEC | May 29, 2026 | — |
| EFFECT | Filing | Feb 13, 2026 | — |
| CORRESP | Letter to the SEC | Feb 11, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 9, 2026 | — |
| DEFR14A | Filing | Oct 27, 2025 | — |
| EFFECT | Filing | Apr 28, 2025 | — |
| CORRESP | Letter to the SEC | Apr 24, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 23, 2025 | — |
| EFFECT | Filing | Apr 10, 2025 | — |
| CORRESP | Letter to the SEC | Apr 8, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 7, 2025 | — |
| POS EX | Filing | Mar 25, 2025 | — |
| DEFC14A | Filing | Oct 31, 2024 | — |
| EFFECT | Filing | Jul 9, 2024 | — |
| CORRESP | Letter to the SEC | Jul 5, 2024 | — |
| 425 | Filing | Mar 7, 2024 | — |
| EFFECT | Filing | Feb 13, 2024 | — |
| CORRESP | Letter to the SEC | Feb 13, 2024 | — |
| CORRESP | Letter to the SEC | Feb 6, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 1, 2024 | — |
| CORRESP | Letter to the SEC | Jan 16, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 18, 2023 | — |
| 425 | Filing | Aug 30, 2023 | — |
| PRER14A | Filing | Oct 5, 2022 | — |
| 425 | Filing | Mar 2, 2021 | — |
| EFFECT | Filing | Jan 29, 2021 | — |
| CORRESP | Letter to the SEC | Jan 26, 2021 | — |
| CORRESP | Letter to the SEC | Jan 26, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 14, 2021 | — |
| CORRESP | Letter to the SEC | Jan 8, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 25, 2020 | — |
| CORRESP | Letter to the SEC | Nov 16, 2020 | — |
| PRER14A | Filing | Nov 16, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 13, 2020 | — |
| CORRESP | Letter to the SEC | Nov 5, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 5, 2020 | — |
| CORRESP | Letter to the SEC | May 22, 2020 | — |
| UPLOAD | Letter from the SEC | May 18, 2020 | — |
| D | Filing | Mar 22, 2019 | — |
| CT ORDER | Filing | Nov 28, 2018 | — |
| SEC STAFF ACTION | Filing | Nov 27, 2018 | — |
| CERT | Nyse certification agex therapeutics, inc. | Nov 27, 2018 | — |
| 10-12B/A | Filing | Nov 26, 2018 | — |
| 10-12B/A | Filing | Nov 5, 2018 | — |
| 10-12B/A | Filing | Oct 22, 2018 | — |
| 10-12B/A | Filing | Aug 30, 2018 | — |
| D | Filing | Aug 27, 2018 | — |
| 10-12B/A | Filing | Jul 19, 2018 | — |
| D | Filing | Jun 21, 2018 | — |
| 10-12B | Filing | Jun 8, 2018 | — |
| D | Filing | Jan 31, 2018 | — |
| D | Filing | Jul 10, 2017 | — |
Showing 55 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SER (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- AL
- Headquarters
- Huntsville, AL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1708599
- Former names
- AgeX Therapeutics, Inc. (until Apr 1, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.